FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
TEL AVIV, Israel, Sept. 28, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview via a Fireside Chat format at the Chardan Gene Therapy Conference, being held October 10th at the Westin New York Grand Central hotel in New York City.
Presentation Details:
Date: Tuesday, October 10
Time: 1:45pm Eastern Time.
Webcast: http://wsw.com/webcast/chard/vblt/
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
[email protected]
(646) 597-6979
MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
(646) 627-8384
